88.38
0.72 (0.82%)
| 前收盘价格 | 87.66 |
| 收盘价格 | 87.65 |
| 成交量 | 554,449 |
| 平均成交量 (3个月) | 786,139 |
| 市值 | 6,062,300,160 |
| 价格/销量 (P/S) | 29.51 |
| 股市价格/股市净资产 (P/B) | 54.02 |
| 52周波幅 | |
| 利润日期 | 4 Aug 2026 |
| 营业毛利率 | -123.28% |
| 营业利益率 (TTM) | -143.73% |
| 稀释每股收益 (EPS TTM) | -2.80 |
| 季度收入增长率 (YOY) | 25.90% |
| 总债务/股东权益 (D/E MRQ) | 69.65% |
| 流动比率 (MRQ) | 3.30 |
| 营业现金流 (OCF TTM) | -113.49 M |
| 杠杆自由现金流 (LFCF TTM) | -96.71 M |
| 资产报酬率 (ROA TTM) | -51.33% |
| 股东权益报酬率 (ROE TTM) | -150.20% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看涨 | 混合的 |
| Biotechnology (全球的) | 看涨 | 混合的 | |
| 股票 | Rhythm Pharmaceuticals, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.0 |
| 技术平均移动指标 | -2.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.88 |
|
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.65% |
| 机构持股比例 | 103.78% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合